Tocqueville Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-4,141
| Closed | -$440K | – | 612 |
|
|
2022
Q3 | $440K | Buy |
4,141
+66
| +2% | +$6.7K | 0.01% | 461 |
|
|
2022
Q2 | $397K | Hold |
4,075
| – | – | 0.01% | 532 |
|
|
2022
Q1 | $382K | Hold |
4,075
| – | – | 0.01% | 566 |
|
|
2021
Q4 | $347K | Hold |
4,075
| – | – | ﹤0.01% | 619 |
|
|
2021
Q3 | $391K | Sell |
4,075
-3,525
| -46% | -$333K | 0.01% | 583 |
|
|
2021
Q2 | $740K | Sell |
7,600
-73
| -1% | -$7K | 0.01% | 491 |
|
|
2021
Q1 | $746K | Hold |
7,673
| – | – | 0.01% | 489 |
|
|
2020
Q4 | $735K | Sell |
7,673
-102
| -1% | -$9.85K | 0.01% | 483 |
|
|
2020
Q3 | $748K | Sell |
7,775
-49
| -0.6% | -$5.67K | 0.01% | 433 |
|
|
2020
Q2 | $955K | Buy |
7,824
+124
| +2% | +$13.7K | 0.02% | 397 |
|
|
2020
Q1 | $666K | Sell |
7,700
-2,500
| -25% | -$245K | 0.02% | 408 |
|
|
2019
Q4 | $1.1M | Sell |
10,200
-9,055
| -47% | -$948K | 0.02% | 440 |
|
|
2019
Q3 | $1.74M | Buy |
19,255
+4,500
| +30% | +$420K | 0.02% | 387 |
|
|
2019
Q2 | $1.25M | Sell |
14,755
-1,829
| -11% | -$150K | 0.02% | 446 |
|
|
2019
Q1 | $1.46M | Sell |
16,584
-1,616
| -9% | -$135K | 0.02% | 422 |
|
|
2018
Q4 | $1.3M | Sell |
18,200
-4,375
| -19% | -$419K | 0.02% | 428 |
|
|
2018
Q3 | $2.78M | Buy |
22,575
+3,500
| +18% | +$397K | 0.04% | 375 |
|
|
2018
Q2 | $1.87M | Buy |
19,075
+1,500
| +9% | +$134K | 0.02% | 431 |
|
|
2018
Q1 | $1.46M | Buy |
17,575
+50
| +0.3% | +$4.22K | 0.02% | 465 |
|
|
2017
Q4 | $1.36M | Hold |
17,525
| – | – | 0.02% | 473 |
|
|
2017
Q3 | $1.07M | Hold |
17,525
| – | – | 0.01% | 519 |
|
|
2017
Q2 | $806K | Sell |
17,525
-2,500
| -12% | -$121K | 0.01% | 526 |
|
|
2017
Q1 | $867K | Sell |
20,025
-4,600
| -19% | -$197K | 0.01% | 511 |
|
|
2016
Q4 | $953K | Sell |
24,625
-9,100
| -27% | -$412K | 0.01% | 497 |
|
|
2016
Q3 | $1.71M | Sell |
33,725
-9,175
| -21% | -$457K | 0.02% | 427 |
|
|
2016
Q2 | $1.95M | Buy |
42,900
+1,800
| +4% | +$82.9K | 0.02% | 416 |
|
|
2016
Q1 | $1.63M | Buy |
41,100
+15,900
| +63% | +$631K | 0.02% | 425 |
|
|
2015
Q4 | $1.43M | Buy |
25,200
+4,000
| +19% | +$203K | 0.02% | 475 |
|
|
2015
Q3 | $844K | Buy |
21,200
+8,000
| +61% | +$387K | 0.01% | 594 |
|
|
2015
Q2 | $630K | Buy |
+13,200
| New | +$560K | 0.01% | 659 |
|
|
2013
Q4 | – | Sell |
-23,350
| Closed | -$264K | – | 1396 |
|
|
2013
Q3 | $264K | Hold |
23,350
| – | – | ﹤0.01% | 812 |
|
|
2013
Q2 | $312K | Buy |
+23,350
| New | +$287K | ﹤0.01% | 768 |
|
Other funds holding NBIX
BG
APM
Tocqueville Asset Management's NBIX Position: Q4 2022 in Review
Tocqueville Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 4,141 shares — an estimated $440K sold.
Tocqueville Asset Management first reported a position in NBIX in Q2 2013 and held it in 32 quarters. The position peaked at $2.78M in Q3 2018. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.
- Tocqueville Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
- Tocqueville Asset Management sold 4,141 Neurocrine Biosciences shares in Q4 2022, an estimated $440K.
- Tocqueville Asset Management first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 32 quarters.
- Tocqueville Asset Management's Neurocrine Biosciences position peaked at $2.78M in Q3 2018.
- 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.
Based on Tocqueville Asset Management's 13F filing for Q4 2022, filed 9 Feb 2023.